OPTIMAL ADMINISTRATION DURATION OF URACIL-TEGAFUR ON ADJUVANT CHEMOTHERAPY FOR COMPLETELY RESECTED STAGE I LUNG ADENOCARCINOMA: RETROSPECTIVE ANALYSIS FROM JLCRG PHASE III STUDY

被引：0
|
作者：
Tsuboi, M. [1 ]
Hamada, C. [2 ]
机构：
[1] Kanagawa Canc Ctr, Yokohama, Kanagawa 2410815, Japan
[2] Tokyo Univ Sci, Fac Engn, Tokyo 162, Japan
[3] Japan Lung Canc Res Grp, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：154 / 154
页数：1
相关论文
共 50 条
  • [21] Effect of Tegafur-Uracil in Resected Stage IB Lung Adenocarcinoma According to Presence or Absence of Epidermal Growth Factor Receptor Gene Mutation: A Retrospective Cohort Study
    Aoki, Masaya
    Miyata, Ryo
    Kamimura, Go
    Takeda, Aya Harada
    Suetsugu, Takayuki
    Mizuno, Keiko
    Ueda, Kazuhiro
    ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 30 (01)
  • [22] Randomised study of adjuvant chemotherapy for completely resected p-stage I–IIIA non-small cell lung cancer
    K Nakagawa
    H Tada
    A Akashi
    T Yasumitsu
    K Iuchi
    T Taki
    K Kodama
    British Journal of Cancer, 2006, 95 : 817 - 821
  • [23] A Phase III Study of Adjuvant Chemotherapy in Patients with Completely Resected, Node-Negative Non-Small Cell Lung Cancer
    Kunitoh, H.
    Sakurai, H.
    Tsuboi, M.
    Wakabayashi, M.
    Okada, M.
    Suzuki, K.
    Ikeda, N.
    Takahama, M.
    Takenoyama, M.
    Ohde, Y.
    Yoshiya, K.
    Matsumoto, I.
    Yamashita, M.
    Marutsuka, T.
    Date, H.
    Hasumi, T.
    Yamashita, Y.
    Okumura, N.
    Watanabe, S.
    Asamura, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S270 - S271
  • [24] A prospective randomized study of adjuvant chemotherapy in completely resected stage III-N2 non-small cell lung cancer
    Zheng Shi Ying
    Jiang Dong
    Li Hong
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S518 - S518
  • [25] Phase III trial of treatment duration for oral uracil and tegafur/leucovorin adjuvant chemotherapy for patients (pts) with stage IIB/III colon cancer: Final results of JFMC33-0502
    Sadahiro, S.
    Tsuchiya, T.
    Sasaki, K.
    Kondo, K.
    Katsumata, K.
    Nishimura, G.
    Kakeji, Y.
    Baba, H.
    Kodaira, S.
    Saji, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S481 - S481
  • [26] Advanced age is associated with lack of administration of adjuvant chemotherapy for completely resected stage IB-III non-small cell lung cancer (NSCLC)
    Riely, Gregory J.
    Seshan, V. E.
    Azzoli, C. G.
    Kris, Mark G.
    Rusch, Valerie W.
    Park, Bernard K.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S454 - S454
  • [27] Advantage of post-operative oral administration of UFT (Tegafur and Uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC)
    Tanaka, F
    Miyahara, R
    Ohtake, Y
    Yanagihara, K
    Fukuse, T
    Hitomi, S
    Wada, H
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1998, 14 (03) : 256 - 262
  • [28] Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer
    Nakagawa, K.
    Tada, H.
    Akashi, A.
    Yasumitsu, T.
    Iuchi, K.
    Taki, T.
    Kodama, K.
    BRITISH JOURNAL OF CANCER, 2006, 95 (07) : 817 - 821
  • [29] ADJUVANT CHEMOTHERAPY FOR COMPLETELY RESECTED STAGE-III NON-SMALL-CELL LUNG-CANCER - RESULTS OF A RANDOMIZED PROSPECTIVE-STUDY
    OHTA, M
    TSUCHIYA, R
    SHIMOYAMA, M
    SAWAMURA, K
    MORI, T
    MIYAZAWA, N
    SUEMASU, K
    WATANABE, Y
    TOMITA, M
    TERASHIMA, M
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1993, 106 (04): : 703 - 708
  • [30] Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502
    Sadahiro, S.
    Tsuchiya, T.
    Sasaki, K.
    Kondo, K.
    Katsumata, K.
    Nishimura, G.
    Kakeji, Y.
    Baba, H.
    Sato, S.
    Koda, K.
    Yamaguchi, Y.
    Morita, T.
    Matsuoka, J.
    Usuki, H.
    Hamada, C.
    Kodaira, S.
    ANNALS OF ONCOLOGY, 2015, 26 (11) : 2274 - 2280
12345